Intellectual Property India Publishes Patent Application for 'Novel, Reversible Dpp1 Inhibitors And Uses Thereof' Filed by Insmed Incorporated

MUMBAI, India, Aug. 22 -- Intellectual Property India has published a patent application (202517073295 A) filed by Insmed Incorporated, Bridgewater, U.S.A., on Aug. 1, for 'novel, reversible dpp1 inhibitors and uses thereof.'

Inventor(s) include Plaunt, Adam J.; Cerdan, Adrien; Ciapetti, Paola; and Goegan, Bastien.

The application for the patent was published on Aug. 22, under issue no. 34/2025.

According to the abstract released by the Intellectual Property India: "Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts or deuterated forms thereof, wherein R0, L and R1 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor."

The patent application was internationally filed on Jan. 05, 2024, under International application No.PCT/US2024/010555.

Disclaimer: Curated by HT Syndication.